Drugs & Targets EC approves Libtayo as adjuvant treatment of high-risk cutaneous squamous cell carcinoma November 21, 2025Vol.51 No.43
Drugs & Targets GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology November 21, 2025Vol.51 No.43
Drugs & Targets Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S. November 21, 2025Vol.51 No.43
Drugs & Targets Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection November 21, 2025Vol.51 No.43
Drugs & Targets Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors November 14, 2025Vol.51 No.42
Drugs & Targets FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma November 07, 2025Vol.51 No.41
Drugs & Targets GSK, Empirico enter license agreement for oligonucleotide candidate to treat respiratory diseases November 07, 2025Vol.51 No.41
Drugs & Targets EMA grants GSK’227 Orphan Drug Designation for pulmonary neuroendocrine carcinoma November 07, 2025Vol.51 No.41
